Tech Company Financing Transactions
Acetylon Pharmaceuticals Funding Round
Acetylon Pharmaceuticals closed a $14.6 million Series B funding round on 6/29/2011. Investors included private investors.
Transaction Overview
Company Name
Announced On
6/29/2011
Transaction Type
Venture Equity
Amount
$14,600,000
Round
Series B
Investors
Proceeds Purpose
The proceeds will be used in part to fund the advancement of the Company's lead drug candidate ACY-1215 -- a next-generation Class II-selective histone deacetylase (HDAC) inhibitor -- into Phase I/II clinical testing for patients with relapsed and relapsed-refractory multiple myeloma. This funding is part of a $27 million series B financing round.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
70 Fargo St. 205
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Acetylon Pharmaceuticals manufactures small molecule drugs to realize the therapeutic potential of histone deacetylase.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Walter Ogier
VP - Bus. Development
Simon Jones
VP - Bus. Development
Catherine Wheeler
VP - Manufacturing
John van Duzer
Browse more venture capital transactions:
Prev: 6/29/2011: HealthGuru Media venture capital transaction
Next: 6/29/2011: Dynamics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs